According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

In a blockbuster pharma merger that shook the global biotech sector, Sanofi announced Friday it has officially completed its ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval for a potential rival to Blueprint Medicines’ Ayvakit.

Blueprint Medicines Corporation (NASDAQ:BPMC) is one of the best biotech stocks to invest in now. On June 12, Blueprint Medicines announced new data reinforcing the sustained clinical efficacy and ...

Fintel reports that on June 2, 2025, JP Morgan downgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from Overweight to Neutral. Analyst Price Forecast Suggests 0.02% Downside As of ...

Fintel reports that on June 4, 2025, Citigroup upgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from Sell to Neutral. Analyst Price Forecast Suggests 0.05% Upside As of June 2, 2025 ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and only approved medicine for advanced and ...

Blueprint Medicines Corporation (NASDAQ:BPMC), a commercial-stage biotechnology company specializing in precision therapies for cancer and rare diseases, has been making significant strides in the ...